Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idrabiotaparinux sodium

X
Drug Profile

Idrabiotaparinux sodium

Alternative Names: Biotinylated idraparinux; SSR 126517; SSR126517E

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Anticoagulants; Antithrombotics; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Discontinued Deep vein thrombosis; Embolism

Most Recent Events

  • 11 Dec 2008 Efficacy data from the phase III EQUINOX trial in Deep vein thrombosis presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008) (ADNM)
  • 03 Sep 2008 Pharmacodynamics data from a clinical trial in Thrombosis presented at the Congress of the European Society of Cardiology (ESC-2008)
  • 30 Jul 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the Thromboses pharmacodynamics section
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top